Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...

The Board will present its formal recommendation regarding director nominees in the Company's definitive proxy statement and ...

Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is ...